Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Vizimpro (dacomitinib) for the Treatment of Non-Small Cell Lung Cancer

EGFR mutations are responsible for approximately 10% to 35% of NSCLC tumours worldwide.

  • Vizimpro®
  • Vizimpro®
  • Vizimpro

Go Top